非侵入性检测在脂肪性肝病中的应用:ESSENCE 3期试验与纵向研究的启示
本综述基于2025年Desert Liver Conference专家小组意见,结合ESSENCE 3期试验(2.4 mg司美格鲁肽治疗活检确诊MASH)及纵向研究,提出用非侵入性检测识别高危MASH患者。专家组建议:受控衰减参数≥280 dB/m且AST≥17 IU/L(女性)或≥20 IU/L(男性)者应进一步确认检测,以筛选可从药物治疗(包括司美格鲁肽)中获益的高危MASH患者。
要点
- 高危MASH患者应通过非侵入性检测识别,以指导药物治疗决策。
- CAP≥280 dB/m且AST≥17 IU/L(女)或≥20 IU/L(男)者需进一步确认检测。
- 确认检测包括VCTE、MRE、ELF评分或影像-血清标志物联合检测。
核心结论
- 对高危MASH且MALO风险最高的患者,应提供药物治疗包括司美格鲁肽。
研究设计与样本
- 综述基于2025年3月Desert Liver Conference专家小组意见,结合ESSENCE 3期试验及纵向研究。
主要发现
- ESSENCE试验研究2.4 mg司美格鲁肽在活检确诊MASH患者中的安全性和有效性,但肝活检在临床实践中不广泛使用。
- 非侵入性检测可用于识别可能患有高危MASH的患者。
关键数值与推荐
- 专家组建议对CAP≥280 dB/m且AST≥17 IU/L(女性)或≥20 IU/L(男性)的患者进行进一步确认检测。
- 确认检测包括振动控制瞬时弹性成像、磁共振弹性成像、增强肝纤维化评分和/或影像-血清生物标志物联合检测。
临床怎么用
- 临床中可先用CAP和AST初筛,对达到上述阈值者再行VCTE、MRE、ELF或联合检测确认高危MASH。
- 确认高危MASH后,可考虑包括司美格鲁肽在内的药物治疗以降低MALO风险。
局限性
- 肝活检未广泛用于临床实践,非侵入性检测策略需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly common globally and is associated with significant morbidity and mortality, necessitating effective treatments to stop its progression. Multiple pharmacologic treatments have been developed for MASH, targeting patients most likely to experience major adverse liver outcomes (MALO). It is therefore of utmost importance to accurately identify patients with at-risk MASH, those with the greatest likelihood of developing cirrhosis and other related MALO who would benefit from these treatments. AIMS: The goal of this review is to summarize expert opinion on the pharmacologic treatment of MASH following the recent approval of semaglutide for this condition in the United States. METHODS: An expert panel was convened as part of the Desert Liver Conference (Scottsdale, AZ, USA) in March 2025 to provide recommendations regarding guidelines for selecting patients who would benefit from MASH pharmacotherapy. RESULTS: The ESSENCE trial studied the safety and efficacy of 2.4 mg semaglutide in patients with biopsy-confirmed MASH, but liver biopsy is not widely deployed in clinical practice. Non-invasive tests (NITs) can be used to identify patients who are likely to have at-risk MASH. The panel recommended targeting patients with controlled attenuation parameter ≥ 280 dB/m and AST ≥ 17 IU/L (females) or ≥ 20 IU/L (males) for additional confirmatory testing, such as vibration-controlled transient elastography, magnetic resonance elastography, enhanced liver fibrosis score and/or combination imaging-serum biomarker tests. CONCLUSIONS: Pharmacologic treatment for MASH, including semaglutide, should be offered to patients with at-risk MASH who are at the highest risk of MALO.
引用
- Alkhouri N, Chalasani N, Younossi Z, et al. Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies. Aliment Pharmacol Ther. 2026. PMID: 41941221. doi:10.1111/apt.70639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。